292135-59-2

Basic information

• Product Name: DPC 423
• Synonyms: DPC 423;1-[3-(AMinoMethyl)phenyl]-N-[3-fluoro-2'-(Methylsulfonyl)[1,1'-biphenyl]-4-yl]-3-(trifluoroMethyl)-1H-pyrazole-5-carboxaMide Hydrochloride;1-[3-(AMinoMethyl)phenyl]-N-[3-fluoro-2'-(Methylsulfonyl)[1,1'-biphenyl]-4-yl]-3-(trifluoroMethyl)-1H-pyrazole-5-carboxaMide Monohydrochloride
• CAS NO: 292135-59-2
• Molecular Formula: C25H21ClF4N4O3S
• Molecular Weight: 568.9708528
• Product Categories: Amines;Aromatics;Heterocycles;Inhibitors;Intermediates & Fine Chemicals;Pharmaceuticals;Aromatics, Heterocycles, Inhibitors, Pharmaceuticals, Intermediates & Fine Chemicals
• Mol File: 292135-59-2.mol
• Article Data: 0

Chemical Properties

• Melting Point: 288 °C
• Appearance: /
• CAS DataBase Reference: DPC 423(CAS DataBase Reference)
• NIST Chemistry Reference: DPC 423(292135-59-2)
• EPA Substance Registry System: DPC 423(292135-59-2)

Safety Data

• Hazardous Substances Data: 292135-59-2(Hazardous Substances Data)

Usage

Description

DPC 423 is a synthetic, competitive, and selective inhibitor of human coagulation factor Xa, characterized by its high potency and oral activity. As a pyrazole antithrombotic agent, it serves as an oral anticoagulant designed to prevent arterial thrombosis, offering a promising pharmaceutical solution for managing blood clotting disorders.

Uses

Used in Pharmaceutical Industry:
DPC 423 is used as an oral anticoagulant for the prevention of arterial thrombosis. Its application is particularly relevant in the treatment and management of conditions where there is an increased risk of blood clot formation, such as atrial fibrillation, deep vein thrombosis, and pulmonary embolism.
The use of DPC 423 as an oral anticoagulant is significant because it provides an alternative to traditional injectable anticoagulants, offering patients a more convenient and non-invasive treatment option. Its selectivity for factor Xa, a key enzyme in the coagulation cascade, allows for targeted inhibition of blood clot formation without affecting other aspects of the coagulation process, potentially reducing the risk of bleeding complications associated with broader-spectrum anticoagulants.
Furthermore, the development of DPC 423 as a potent and orally-active agent represents an advancement in the field of antithrombotic drug development, as it addresses the need for more effective and safer anticoagulant therapies. Its synthetic nature and competitive inhibition mechanism contribute to its potential for improved pharmacokinetic properties and reduced drug-drug interactions, making it a valuable addition to the arsenal of treatments for arterial thrombosis and related conditions.